Ibrutinib

SAN DIEGO — A multidrug combination significantly improved survival for certain patients with leukemia compared with standard chemoimmunotherapy, according to results of the randomized phase 3 AMPLIFY study.

SAN DIEGO — Rilzabrutinib induced “fast” and “persistent” platelet count expansion for heavily treated individuals with immune thrombocytopenia, according to results of the randomized phase 3 LUNA 3 study.

The Centers for Medicare & Medicaid Services announced lower Medicare Part D prices for 10 drugs that will take effect in 2026, according to a press release.

In a video interview, Matthew Cortese, MD, MPH, discusses how AI could transform the treatment landscape for CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses the importance of long-term monitoring in CLL care.

In a video interview, Matthew Cortese, MD, MPH, discusses strategies to combat infections in CLL patients.

In a video interview, Matthew Cortese, MD, MPH, discusses advances in treatments for relapse/refractory CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses how to approach initial treatment of CLL.

A simultaneous, multidrug, multi-targeted treatment regimen produced remissions in patients with certain types of relapsed or refractory diffuse large B-cell lymphoma in a phase 1b/phase 2 study.

The combination treatment of two or more antihypertensive therapies in patients being treated with ibrutinib can significantly reduce blood pressure, data published in Blood Advances showed.